The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLong Ideas - When a biotechnology company is around 20 years after its incorporation, common wisdom would suggest that it has become a major player in the biotechnology … Continue Reading
Read nowMost Popular - Gilead paid a lot of money – $11B to be exact – to acquire Pharmasset back in 2011. Was it worth it? Propthink dug in … Continue Reading
Read nowMost Popular - Hepatitis C drug developers have been swiftly moving towards interferon-free, oral regimens, and while Vertex’s (NASDAQ:VRTX) Incivek was briefly the lead treatment in the field, … Continue Reading
Read nowMost Popular - Shares of Questcor Pharmaceuticals (NASDAQ:QCOR) are under pressure Friday, down 10% in morning trading on news that unknown drug company Cerium Pharmaceuticals has received Orphan … Continue Reading
Read nowResearch - In November of 2011, Gilead announced that it reached an agreement to purchase Pharmasset for $11 billion, an 89% premium to its previous close. CEO … Continue Reading
Read nowLong Ideas - Shares of Endo Pharmaceuticals (NASDAQ:ENDP) are trading at a deep discount to other pharmaceutical companies, with the last dip in price coming on the heels … Continue Reading
Read nowLong Ideas - Onyx Pharmaceuticals (NASDAQ:ONXX) got the better of earnings estimates for the 3rd quarter of 2012, with non-GAAP net loss per share of $.79 compared to … Continue Reading
Read now
